Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...

Peers & Perspectives® in Oncology delivers exclusive coverage of virtual and in-person live events held by Targeted Oncology and Healthcare Research & Analytics®, thought leader collaborations, and ...

ENDURANCE randomized 516 standard-risk, transplant-deferred patients after PI–lenalidomide induction to indefinite vs 2-year lenalidomide maintenance, powered for a 50% median OS improvement.

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...